Allan C deCamp
Overview
Explore the profile of Allan C deCamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesselman M, Zeeb M, Rusert P, Pasin C, Mamrosh J, Kariuki S, et al.
Cell Host Microbe
. 2025 Feb;
33(2):279-293.e6.
PMID: 39909038
Identifying HIV-1 envelope (Env) traits associated with neutralization cross-reactivity is crucial for vaccine design. Variable loops 1 and 2 (V1V2), positioned at the Env trimer apex, are key regions linked...
2.
Cohen P, Lambson B, Mkhize N, Moodley C, Yssel A, Moyo-Gwete T, et al.
J Virol
. 2025 Jan;
99(2):e0173024.
PMID: 39817771
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against...
3.
Kalams S, Felber B, Mullins J, Scott H, Allen M, De Rosa S, et al.
JCI Insight
. 2024 Aug;
9(18).
PMID: 39088271
BACKGROUNDAn HIV-1 DNA vaccine composed of 7 highly conserved, structurally important elements (conserved elements, CE) of p24Gag was tested in a phase I randomized, double-blind clinical trial (HVTN 119, NCT03181789)...
4.
Cantos V, Neradilek M, Huang Y, Roxby A, Gillespie K, deCamp A, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae387.
PMID: 39035572
Background: HIV Vaccine Trials Network (HVTN) 704/085, a placebo-controlled clinical trial assessing the efficacy of VRC01 broadly neutralizing antibody infusion for HIV prevention, offered oral preexposure prophylaxis (PrEP) as the...
5.
Mayer B, Zhang L, deCamp A, Yu C, Sato A, Angier H, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794258
Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays...
6.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.
7.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
NPJ Vaccines
. 2024 Mar;
9(1):58.
PMID: 38467663
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8...
8.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
9.
Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(4):e2308942121.
PMID: 38241441
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition...
10.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2023 Dec;
14(1):8299.
PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...